https://www.selleckchem.com/products/nhwd-870.html
36%, P= .02; EFS 35% vs. 0%, P= .03). Significant prognostic factors for EFS on multivariate analysis were the achievement of molecular remission (50 copies of WT1) at any time during treatment (hazard ratio [HR] 0.47, P= .04) and increased WT1 expression after 2 cycles of chemotherapy (HR 2.0, P= .03). Increased WT1 expression after 2 cycles of chemotherapy is a negative prognostic factor for survival. WT1 remains a valuable molecular marker in AML without any leukemia-specific mutation, especially if next generation sequencing an
Like
Comment
Share
